ClinicalTrials.gg
Not yet recruitingNCT07144995Updated Aug 28, 2025

MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma

An observational study in Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma and Fruquintinib, sponsored by Sun Yat-sen University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Sun Yat-sen University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1,143
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Stomach Neoplasms by Sun Yat-sen University — 6 open to participants now, 7 under way, 2 of them phase 3. Stomach Neoplasms · Sun Yat-sen University.

Started
2025
the only one that year
Observational
6 of 29
1 open now
Registered
29th of 29
by date

Among the 29 studies in Stomach Neoplasms by Sun Yat-sen University, this one is the only one that started in 2025, is one of 6 observational ones, and was the 29th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 29 studies in Stomach Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Stomach Neoplasms by Sun Yat-sen University, or all of them as a file.
02

Study summary

This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia, n=440) in advanced gastric/GEJ adenocarcinoma. Baseline characteristics are adjusted via entropy balancing weights. Primary endpoint is progression-free survival (PFS) analyzed by Bucher method; secondary endpoints include overall survival (OS) and objective response rate (ORR). Sensitivity analyses comprise restricted mean survival time (RMST) analysis and simulated treatment comparison (STC).

Read the detailed description

This retrospective MAIC analysis employs individual patient data (IPD) from the FRUTIGA trial (fruquintinib arm) and published aggregate data (AgD) from RAINBOW-Asia (ramucirumab arm), with placebo as the common anchor. Pseudo individual participant data (Pseudo-IPD) for the RAINBOW-Asia trial were reconstructed from published Kaplan-Meier curves using the Guyot algorithm (2012).

•Weighting Methodology: Seven prognostic factors balanced: age \<65, male sex, ECOG 0, GEJ primary, peritoneal metastases, metastatic sites, prior doublet chemotherapy Optimization via BFGS algorithm (convergence tolerance 1e-6) Effective sample size (ESS) retention: > 50%

•Statistical Analysis: Primary: Adjusted PFS hazard ratio (HR) using Bucher method with 95% bootstrap CI (100 iterations) Secondary: Weighted Cox models for OS; logistic regression for ORR/DCR Sensitivity: Simulated Treatment Comparison (STC) and covariate threshold analyses

•Sensitivity Analyses: RMST analyses were conducted as supportive evidence alongside primary Cox models for time-to-event endpoints violating proportional hazards assumptions.

Restricted mean survival time (RMST) Simulated Treatment Comparison (STC) Bootstrap confidence intervals (100 iterations)

03

Conditions studied

  • Advanced Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Fruquintinib
  • Ramucirumab

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This retrospective MAIC analysis employs individual patient data (IPD) from the FRUTIGA trial (fruquintinib arm) and published aggregate data (AgD) from RAINBOW-Asia (ramucirumab arm), with placebo as the common anchor.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed gastric/GEJ adenocarcinoma
  • Advanced or disease
  • 0-1
  • Received either fruquintinib + paclitaxel or reference regimen
  • Available baseline characteristics for matching variables

Exclusion criteria

Exclusion Criteria:

  • Missing key outcome data
  • Incomplete baseline characteristics for >2 matching variables
  • Prior fruquintinib exposure (control arm only)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1,143 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fruquintinib + paclitaxel

    Group 1: Fruquintinib + Paclitaxel (IPD)

    Drug: Fruquintinib+Paclitaxel

  • Ramucirumab + paclitaxel

    Group 2: Control Therapy (AgD from RAINBOW-Asia)

    Drug: Ramucirumab+Paclitaxel

Interventions

  • DrugFruquintinib+Paclitaxel

    Drug pages: HMPL-013Studies of HMPL-013HMPL-013 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    (using IPD from the FRUTIGA trial, n=703) Fruquintinib:subjects received Fruquintinib orally, once daily for 3 wks on/ 1 wk off Paclitaxel:Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.

    Also known as: HMPL-013+paclitaxel

  • DrugRamucirumab+Paclitaxel

    Drug pages: RamucirumabStudies of RamucirumabRamucirumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    (using published AgD from RAINBOW-Asia, n=440) Ramucirumab:8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle Paclitaxel :Paclitaxel 80mg/㎡ at day 1,8,15 of 4-week cycle.

    Also known as: LY3009806 +paclitaxel

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time from randomization to progression/death, assessed via weighted Cox model

    Time frame: about 3 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    CR+PR per RECIST 1.1, compared via weighted logistic regression

    Time frame: about 3 years

  2. Disease Control Rate (DCR)

    CR+PR+SD≥6 weeks, analyzed via weighted proportions

    Time frame: about 3 years

  3. Overall Survival (OS)

    Time from randomization to death, analyzed using weighted Kaplan-Meier

    Time frame: about 3 years

  4. PFS by ECOG, metastasis burden, primary site, etc

    To examine the associations between subgroup factors (including ECOG, metastasis burden, primary site, etc) and Progression-Free Survival (PFS).

    Time frame: about 3 years

  5. OS by ECOG, metastasis burden, primary site, etc

    To examine the associations between subgroup factors (including ECOG, metastasis burden, primary site, etc) and Overall Survival (OS).

    Time frame: about 3 years

Other outcomes

  1. Sensitivity Analyses:Progression-Free Survival (PFS)

    Simulated Treatment Comparison (STC), Bootstrap confidence intervals (100 iterations)

    Time frame: about 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — This study utilizes aggregated data from published literature and de-identified IPD authorized by Hutchison Medipharma Limited. Secondary analysis generated by our team will be shared.

Supporting information: Statistical analysis plan

Time frame: Within 6 months after main publication.

Access criteria: Secondary analysis generated by our team require approval by an independent review committee and a signed data use agreement.

Data sharing details ↗ · www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Aug 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 28, 2025
StartEst.
Sep 5, 2025
Primary completionEst.
Aug 5, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07144995
Responsible party
Feng Wang (Professor, Sun Yat-sen University) — Principal investigator
First posted
Aug 28, 2025
Start date
Sep 5, 2025 (estimated)
Primary completion
Aug 5, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 28, 2025

Study contacts

Feng Wang
Contact
wangfeng@sysucc.org.cn
020-8734-3571
Feng Wang
principal investigator · Sun Yat-sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion